-
Mashup Score: 1Dravet Syndrome Clinical Trial With STK-001 Continues - 1 year(s) ago
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study, which is evaluating STK-001 in patients with Dravet syndrome.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dravet Syndrome Clinical Trial With STK-001 Continues - 1 year(s) ago
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study, which is evaluating STK-001 in patients with Dravet syndrome.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study evaluating STK-001 in patients with Dravet syndrome. https://t.co/Y8K9aJW7Jj @StokeTx @curedravet @DSFeu @DravetUK @NIH #DravetSyndrome #StokeTherapeutics #raredisease
-
-
Mashup Score: 0Dravet Syndrome Clinical Trial With STK-001 Continues - 1 year(s) ago
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study, which is evaluating STK-001 in patients with Dravet syndrome.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study evaluating STK-001 in patients with Dravet syndrome. https://t.co/Y8K9aJW7Jj @StokeTx @curedravet @DSFeu @DravetUK @NIH #DravetSyndrome #StokeTherapeutics #raredisease
-
-
Mashup Score: 1Dravet Syndrome Clinical Trial With STK-001 Continues - 1 year(s) ago
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study, which is evaluating STK-001 in patients with Dravet syndrome.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study evaluating STK-001 in patients with Dravet syndrome. https://t.co/Y8K9aJW7Jj @StokeTx @curedravet @DSFeu @DravetUK @NIH #DravetSyndrome #StokeTherapeutics #raredisease
-
-
Mashup Score: 0Dravet Syndrome Clinical Trial With STK-001 Continues - 1 year(s) ago
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study, which is evaluating STK-001 in patients with Dravet syndrome.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study evaluating STK-001 in patients with Dravet syndrome. https://t.co/Y8K9aJW7Jj @StokeTx @curedravet @DSFeu @DravetUK @NIH #DravetSyndrome #StokeTherapeutics #raredisease
-
-
Mashup Score: 0CheckRare Featured Podcasts - 1 year(s) ago
Rare disease podcasts and discussions with leading experts.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don't forget... You can listen and subscribe to CheckRare podcasts. https://t.co/yaDibZKzMg Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, gives a detailed overview of Dravet syndrome. @curedravet @DravetUK @StokeTx #StokeTherapeutics #raredisease https://t.co/3XQ0M6kfnN
-
-
Mashup Score: 0Dravet Syndrome Clinical Trial With STK-001 Continues - 1 year(s) ago
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study, which is evaluating STK-001 in patients with Dravet syndrome.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study evaluating STK-001 in patients with Dravet syndrome. https://t.co/Y8K9aKdIAR @StokeTx @curedravet @DSFeu @DravetUK @NIH #DravetSyndrome #StokeTherapeutics #raredisease
-
Barry S. Ticho, MD, PhD, Chief Medical Officer at Stoke Therapeutics, discusses the phase 1/2a MONARCH study evaluating STK-001 in patients with Dravet syndrome. https://t.co/Y8K9aJW7Jj @StokeTx @curedravet @DSFeu @DravetUK @NIH #DravetSyndrome #StokeTherapeutics #raredisease